Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Epilepsy 2Tuberous Sclerosis Complex-associated Refractory Seizures 1Tuberous Sclerosis 1Seizures 1Gliosarcoma 1Glioma 1Glioblastoma 1Drug Resistant Epilepsy 1Cognitive Dysfunction 1Chronic Pain 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Levetiracetam 6Cannabidiol 5perampanel 2Tranexamic Acid 2Standard of Care 2Everolimus 2ziprasidone 1enzalutamide 1Zolpidem 1Warfarin 1Vigabatrin 1Vecuronium Bromide 1Vancomycin 1Tobramycin 1Temozolomide 1Spironolactone 1Solutions 1Sodium Chloride 1Sevelamer 1Saline Solution 1Rocuronium 1Remifentanil 1Propofol 1Pregabalin 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1Nifedipine 1Nafcillin 1Molindone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Seizures × Anticonvulsants × Clear all
NCT03356769 2020-06-09

Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex

Peking Union Medical College Hospital

Phase 2 Unknown
98 enrolled

Epilepsy, Seizures, Tuberous Sclerosis, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡